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Background: With the advent of percutaneous coronary intervention, specifically the bare metal stent and
subsequently, the drug-eluting stent, the scope of interventional cardiology has greatly increased. Aspirin, in combination
with a thienopyridine is the present-day cornerstone of oral antiplatelet therapy after coronary artery stent placement.
Continuing this chronic antiplatelet therapy, to mitigate a perioperative major adverse cardiac event, can be challenging
and remains controversial in patients with a coronary artery stent undergoing non-cardiac surgery. We describe here the
rationale for and successful use of an alternate approach to formulating local institutional management protocols
for patients with a coronary artery stent, undergoing an elective surgical procedure.
Discussion: A recent systematic review identified 11 clinical practice guidelines for the perioperative management
of antiplatelet therapy in patients with a coronary stent who need non-cardiac surgery. However, there is significant
variance and inadequacy with these current applicable professional society guidelines. Moreover, persistently variable
success has been experienced in translating even well-grounded national clinical guidelines into local practice,
including in the perioperative setting. Under the auspices of a broadly multidisciplinary institutional task force
and applying the Consensus-Oriented Decision-Making model, we created two evidence-informed and local expert
opinion-supported standardized clinical assessment and management plans for the preoperative management of
antiplatelet therapy in patients with a coronary artery stent.
Summary: Patient care can be optimized via evidence-based, yet locally developed and reiterative standardized
clinical assessment and management plans for patients with coronary artery stents undergoing surgical procedures.
Such standardized clinical assessment and management plans can result in greater consistency in care, providing a
positive feedback loop in which the care plan itself can be continuously reevaluated, improved, and brought up to date
with the most recent available data and knowledge.
Keywords: Coronary artery stent, Antiplatelet therapy, Preoperative, Major adverse cardiac event, Standardized clinical
assessment and management plan, Consensus-oriented decision-making model“Success is simple. Do what’s right, the right way, at
the right time.”
Arnold H. Glasgow (1905-1998), American
Businessman and Humorist
Background
With the advent of percutaneous coronary intervention
(PCI), specifically the bare metal stent (BMS) and* Correspondence: tvetter@uab.edu
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unless otherwise stated.subsequently, the drug-eluting stent (DES), the scope of
interventional cardiology has greatly increased [1-3]. An
estimated 600,000 coronary artery stents are placed an-
nually in the United States (US) for the management of
acute and chronic coronary artery disease [4]. Given the
aging US population and its increasing prevalence of
coronary artery disease, the use of coronary artery stents
will likely continue to grow. These biomedical devices
appear to have reduced the number of more invasive
coronary artery bypass surgeries [1,4]. However, US
Medicare expenditures for drug-eluting stents alone (not
including the cost of chronic antiplatelet drugs) aretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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expected to increase [5].
Aspirin, in combination with a thienopyridine (e.g.,
clopidogrel), is the present-day cornerstone of oral anti-
platelet therapy for the prevention of acute stent throm-
bosis, after placement of a BMS or a DES [6,7]. The
cumulative incidence of non-cardiac surgery following
coronary artery stenting is more than 10% at one year
and over 20% at two years [8]. Continuing this chronic
antiplatelet therapy, to mitigate a perioperative major
adverse cardiac event (MACE), can be challenging and
remains controversial in patients with a coronary artery
stent undergoing non-cardiac surgery [9-11]. While ap-
plicable evidence-based guidelines have been promul-
gated, we observed that they can lack timeliness, clarity,
and applicability—resulting in variation in actual use. We
thus describe here the rationale for and successful use of
an alternate approach to formulating local institutional
management protocols for patients with a coronary artery
stent undergoing an elective surgical procedure.
Existing Guidelines for the Perioperative Management of
Antiplatelet Therapy in Patients with a Coronary Artery
Stent
A recent systematic review identified 11 clinical practice
guidelines for the perioperative management of anti-
platelet therapy in patients with a coronary stent who
need non-cardiac surgery [12]. These authors applied
the Appraisal of Guidelines Research and Evaluation II
(AGREE II) instrument (with a maximum score of 161)
to assess the quality of the identified guidelines [12],
Five of the 11 practice guidelines had an AGREE II
score of > 100: American College of Chest Physicians
[13], American College of Cardiology/ American Heart
Association (ACC/AHA) [14], Canadian Cardiovascular
Society [15], European Society for Cardiology [16], and
Institute for Clinical Systems Improvement [17]. The
Society of Thoracic Surgeons has also published updated
guidelines on the management of antiplatelet therapy in
cardiac and non-cardiac surgical patients [18].
However, despite some having AGREE II scores of
greater than 100, a paucity of available definitive evi-
dence has resulted in perioperative coronary artery stent
guidelines that are divergent and vague on key issues.
Recommendations vary regarding the amount of time
which must elapse between stent placement and elective
surgery in order to have an acceptable risk of acute stent
thrombosis when dual antiplatelet therapy (DAPT) is
discontinued. If DAPT must be interrupted within this
critical period due to the risk of bleeding, the recom-
mended timing of aspirin and thienopyridine discontinu-
ation also varies.
These existing guidelines provide well-defined—albeit
contradictory—recommendations on how long electiveprocedures should be delayed following coronary stent
placement. However, for patients needing urgent surgery,
while still presumably requiring DAPT, the recommenda-
tions concerning antiplatelet medications become vague.
Most of the guidelines simply advise somehow weighing
the risk of stent thrombosis against the risk of bleeding
and, if at all possible, continuing the DAPT therapy
throughout the perioperative period. The most current
ACC/AHA guidelines [14,19] do thoroughly review many
of the risks associated with both stent thrombosis and
surgical bleeding, but the incorporation of these risks
into the final recommendations is incomplete.
The Challenges of Implementing Professional Society
Practice Guidelines
Developing such clinical practice guidelines is a highly-
structured, labor intensive process, involving a rigorous
review and critical appraisal of the literature, multidis-
ciplinary consultation, and grading of the resulting rec-
ommendations based on the quality of available evidence
[20]. Nevertheless, persistently variable success has been
experienced in translating even well-grounded national
clinical guidelines into local practice, including in the
perioperative setting [21]. Barriers to providers adopting
such clinical guidelines include inadequate understanding,
lack of agreement and perceived “real-world” practicality,
concerns about loss of self-efficacy, low outcome expecta-
tions, and the inertia of existing practice [22].
In an October 2010 survey of United States Department
of Veterans Affairs network physicians, 100% of anesthesi-
ologists, 100% of cardiologists, but only 78% of surgeons
were aware of the then current ACC/AHA Guidelines
on Perioperative Cardiovascular Evaluation and Care for
Noncardiac Surgery [23]. Furthermore, among the survey
respondents, 87% of anesthesiologists, 90% of cardiologists,
but only 64% of surgeons agreed with these published
guidelines. There was also significant variability among the
three specialties in the perception of risk of coronary stent
thrombosis versus bleeding and in the perioperative con-
tinuation of antiplatelet therapy with a BMS or a DES—
with anesthesiologists and cardiologists emphasizing stent
thrombosis risk and more often electing to continue anti-
platelet therapy [23]. Anecdotally, at our institution, we
had encountered minimal success in achieving consistent
adherence to these same previously published ACC/AHA
clinical practice guidelines for the preoperative manage-
ment of patients with a coronary artery stent.
The Creation of a Standardized Clinical Assessment and
Management Plan for Pre-Procedural Antiplatelet Therapy
in Patients with a Coronary Artery Stent
Neuman and colleagues at the University of Pennsylvania
have observed that the durability of class I guideline recom-
mendations for procedures and treatments, promulgated
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guidelines and levels of evidence [24]. Specifically, of 619
such ACC/AHA recommendations examined, 80.0% were
retained in the subsequent guideline version, 9.2% were
downgraded or reversed, and 10.8% were omitted. Down-
grades, reversals, and omissions were most common
among recommendations that were not supported by mul-
tiple randomized studies [24]. As noted in the accompany-
ing editorial, in order for practice guidelines to be most
effective, they need to be kept up-to-date [25].
The Institute of Medicine (IOM) has recommended
that clinical practice guidelines should be updated when
new evidence suggests the need for modification of such
clinically important recommendations [26]. However, as
noted in the above editorial: “But what does this mean,
and how is it best accomplished?” [25]. To address this,
three additional key questions should be considered: (1)
When is there sufficient new evidence to “trigger” an up-
date; (2) Once a trigger has been met, what methods can
be used to expeditiously produce the update; (3) OnceFigure 1 Protocol for Preoperative Antiplatelet Therapy with Bare Methe update is completed, how is the information best
communicated to relevant stakeholders? [25].
We posit that a standardized clinical assessment and
management plan represents a viable response to the
second and third key questions.
In contrast to professional society practice guidelines,
a standardized clinical assessment and management
plan (SCAMP) provides for a more “homegrown,” local
clinician-designed and clinician-driven, yet rigorous al-
ternative approach to achieving evidence-informed best
practice for a heterogeneous patient population [27].
Clinicians are more likely to adopt practice guidelines
that combine existing evidence and expert opinion in a
format that can be readily revised. An iterative SCAMP
hence accommodates local patients’ individual and popu-
lation differences, respects local providers’ clinical acu-
men, and keeps pace with the rapid growth of medical
knowledge [28]. For example, the published ACC/AHA
guidelines, which were included in the above systematic
review of perioperative management of antiplatelet therapy,tal Stent (BMS).
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guidelines are currently undergoing revision.
With this in mind, under the auspices of a broadly
multidisciplinary Anticoagulation Task Force at the
University of Alabama at Birmingham (List of Stake-
holder), we created two current evidence-informed
yet also local expert opinion-supported SCAMPs: one
focused on preoperative antiplatelet therapy with a BMS
(Figure 1) and one focused on preoperative antiplatelet
therapy with a DES (Figure 2). In that this continuous
quality improvement (CQI) project was not human
subjects research, approval was not obtained from the
Institutional Review Board of the University of Alabama at
Birmingham.
List of University of Alabama at Birmingham Health
System Anticoagulation Task Force Stakeholder Members










Over a 12-month period, our multidisciplinary antic-
oagulation task force applied the Consensus-Oriented
Decision-Making (CODM) model to arrive at a consen-
sus among the local clinical stakeholders. A detailed,
step-wise process, the CODM model can be applied in
any type of decision-making process (Figure 3). It out-
lines a process in which proposals can be collaboratively
built with full participation of all stakeholders [29]. Con-
sensus decision-making does not require unanimity but
instead seeks the agreement of the majority of partici-
pants as well as the resolution or mitigation of minority
held objection [30]. We took into consideration previously
published applicable guidelines and other literature to
create two evidence-informed protocols (see Additional
file 1). These two protocols are presented here as suggested
clinical management approaches.ting Stent (DES).
Figure 3 The Seven Steps Involved in the Consensus-Oriented
Decision-Making (CODM) model [29].
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It should be noted that our two present coronary artery
SCAMPs are not evidence-based per se, pending add-
itional published data. The central management principle
that emerges from the present authors’ algorithms and the
above existing guidelines [12,18] is the need to assess stent
thrombotic risk (from preoperative withdrawal of anti-
platelet therapy) versus bleeding risk (from perioperative
continuation of antiplatelet therapy) for each surgical
patient. Likewise, appropriate consideration is given to
surgical procedures that are deemed urgent (e.g., cancer-
related) and thus cannot be delayed until the time period
of highest risk for acute coronary artery stent thrombosis
has passed.
Our present recommendations provide greater clarity
for the large majority of surgical patients. However, man-
agement of patients with a recently placed DES and risk
factor(s) for acute stent thrombosis, undergoing intracra-
nial or intraspinal surgery, remained controversial among
our clinical stakeholders. In such situations, we advise that
a formal Cardiology consult be obtained and bridging ther-
apy be considered for such patients.
Once approved by our institutional medical executive
committee (comprised primarily of our clinical departmental
chairs, including all of our surgical departments), these
SCAMPs were implemented health system-wide in January
2014, so as to provide standardized care to procedural
patients with a BMS or DES. The clear stakeholder expect-
ation is that these two SCAMPs will be promptly revised
as pertinent new outcomes data or national organizational
recommendations become available—again applying the
CODM model.
Since their implementation only recently occurred, we
do not have any clinical outcomes data to support the
effectiveness of the two coronary artery stent SCAMPs
at our institution. However, our planned quality assur-
ance metrics include: 1) compliance rates with both
SCAMPs; 2) number of surgical cases cancelled because
of adherence and non-adherence to the applicable SCAMP;
and 3) incidence of major bleeding events (including drop
in hemoglobin below 8 g/dL, need for packed red blood
cell or platelet transfusion) in patients on DAPT not
discontinued prior to surgery; and 4) incidence of peri-
operative MACE.
Summary
The need for continuing chronic antiplatelet therapy for
coronary artery stents can be challenging and remains
controversial in patients undergoing surgery. These
challenges and controversies can best be addressed with
an understanding of the pharmacology and applicable
pharmacogenomics of antiplatelet drugs, continued evo-
lution of the coronary artery stent, and pathophysiology
and epidemiology of perioperative MACE with such
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based, yet locally developed and reiterative SCAMPs for
patients with coronary artery stents undergoing surgical
procedures. These patient-specific SCAMPs include not
only the type of stent, indication, and elapsed time since
placement, but also the stratified level of risk of morbidity
and mortality from procedure-related bleeding. Such
SCAMPs can result in greater consistency in care, provid-
ing a positive feedback loop in which the care plan itself
can be continuously reevaluated, improved, and brought
up to date with the most recent data and knowledge.
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